B. Metzler seel. Sohn & Co. AG Cuts Stock Position in Revolution Medicines, Inc. $RVMD

Key Points

• B. Metzler seel. Sohn & Co. AG cut its stake in Revolution Medicines by 32.5% in Q4, leaving it with 17,440 shares valued at $1.389M, while institutional investors now own 94.34% of the company.
• Significant insider selling: insiders sold a total of 184,592 shares worth $24.5M over the last 90 days, including Mark A. Goldsmith's sale of 120,000 shares for $18.01M; insiders still hold 8.20% of shares.
• Shares opened at $135.30 (52-week range $34.00–$155.70); the company reported an EPS miss of ($1.86) vs. ($1.56) consensus, and analysts carry a consensus Buy rating with a $78.94 price target.

B. Metzler seel. Sohn & Co. AG lessened its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 32.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,440 shares of the company's stock after selling 8,381 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Revolution Medicines were worth $1,389,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co purchased a new stake in Revolution Medicines in the 4th quarter worth $32,000. Darwin Wealth Management LLC purchased a new stake in Revolution Medicines in the 4th quarter worth $40,000. Signaturefd LLC increased its holdings in Revolution Medicines by 33.1% in the 4th quarter. Signaturefd LLC now owns 656 shares of the company's stock worth $52,000 after acquiring an additional 163 shares in the last quarter. CWM LLC increased its holdings in Revolution Medicines by 51.6% in the 4th quarter. CWM LLC now owns 702 shares of the company's stock worth $56,000 after acquiring an additional 239 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Revolution Medicines by 44.7% in the 4th quarter. Farther Finance Advisors LLC now owns 751 shares of the company's stock worth $60,000 after acquiring an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Revolution Medicines Stock Performance

Shares of RVMD opened at $135.30 on Monday. Revolution Medicines, Inc. has a 52-week low of $34.00 and a 52-week high of $155.70. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The firm's fifty day moving average is $107.56 and its two-hundred day moving average is $89.80. The stock has a market cap of $26.81 billion, a PE ratio of -22.89 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the prior year, the business earned ($1.12) EPS. Research analysts forecast that Revolution Medicines, Inc. will post -7.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on RVMD. UBS Group began coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a "buy" rating for the company. HC Wainwright reissued a "buy" rating on shares of Revolution Medicines in a report on Wednesday, April 22nd. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a "buy" rating for the company. Evercore reissued an "outperform" rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $78.94.

Insider Activity at Revolution Medicines

In other news, insider Xiaolin Wang sold 2,010 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the transaction, the insider owned 116,063 shares of the company's stock, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark A. Goldsmith sold 120,000 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the transaction, the insider directly owned 276,698 shares in the company, valued at approximately $41,529,602.82. The trade was a 30.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 184,592 shares of company stock worth $24,499,532 over the last 90 days. Corporate insiders own 8.20% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.